195 related articles for article (PubMed ID: 36866496)
1. Risk of Severe Hypoglycemia With Newer Second-line Glucose-lowering Medications in Older Adults With Type 2 Diabetes Stratified by Known Indicators of Hypoglycemia Risk.
Htoo PT; Paik JM; Alt E; Kim DH; Wexler DJ; Kim SC; Patorno E
J Gerontol A Biol Sci Med Sci; 2023 Dec; 78(12):2426-2434. PubMed ID: 36866496
[TBL] [Abstract][Full Text] [Related]
2. A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.
Fu EL; Mastrorilli J; Bykov K; Wexler DJ; Cervone A; Lin KJ; Patorno E; Paik JM
Kidney Int; 2024 Mar; 105(3):618-628. PubMed ID: 38101515
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.
McCoy RG; Van Houten HK; Deng Y; Mandic PK; Ross JS; Montori VM; Shah ND
JAMA Netw Open; 2021 Feb; 4(2):e2035792. PubMed ID: 33523188
[TBL] [Abstract][Full Text] [Related]
4. Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study.
Newman TV; Munshi KD; Neilson LM; Good CB; Swart ECS; Huang Y; Henderson R; Parekh N
J Manag Care Spec Pharm; 2021 Apr; 27(4):435-443. PubMed ID: 33769857
[No Abstract] [Full Text] [Related]
5. Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.
Yang CT; Yang CY; Ou HT; Kuo S
Cardiovasc Diabetol; 2020 Jun; 19(1):83. PubMed ID: 32534570
[TBL] [Abstract][Full Text] [Related]
6. Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels.
D'Andrea E; Wexler DJ; Kim SC; Paik JM; Alt E; Patorno E
JAMA Intern Med; 2023 Mar; 183(3):242-254. PubMed ID: 36745425
[TBL] [Abstract][Full Text] [Related]
7. Comorbidities and neighborhood factors associated with prescription of sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists among medically underserved populations.
Ogunsanmi DO; Harrison AT; Pakker AR; Kovesdy CP; Bailey JE; Surbhi S
J Manag Care Spec Pharm; 2023 Jun; 29(6):699-711. PubMed ID: 37276038
[No Abstract] [Full Text] [Related]
8. SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes.
Zhuo M; Paik JM; Wexler DJ; Bonventre JV; Kim SC; Patorno E
Am J Kidney Dis; 2022 Jun; 79(6):858-867.e1. PubMed ID: 34762974
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
Gonzalez J; Bates BA; Setoguchi S; Gerhard T; Dave CV
Cardiovasc Diabetol; 2023 Mar; 22(1):54. PubMed ID: 36899387
[TBL] [Abstract][Full Text] [Related]
10. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.
Dave CV; Kim SC; Goldfine AB; Glynn RJ; Tong A; Patorno E
Circulation; 2021 Feb; 143(8):770-779. PubMed ID: 33302723
[TBL] [Abstract][Full Text] [Related]
11. Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies.
Hidayat K; Du X; Shi BM
Osteoporos Int; 2019 Oct; 30(10):1923-1940. PubMed ID: 31134305
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults.
Patorno E; Pawar A; Bessette LG; Kim DH; Dave C; Glynn RJ; Munshi MN; Schneeweiss S; Wexler DJ; Kim SC
Diabetes Care; 2021 Mar; 44(3):826-835. PubMed ID: 33495295
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
Lin DS; Lee JK; Hung CS; Chen WJ
Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
[TBL] [Abstract][Full Text] [Related]
14. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes.
Zhuo M; D'Andrea E; Paik JM; Wexler DJ; Everett BM; Glynn RJ; Kim SC; Patorno E
JAMA Netw Open; 2022 Oct; 5(10):e2235995. PubMed ID: 36219443
[TBL] [Abstract][Full Text] [Related]
15. Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives.
Seino Y; Kuwata H; Yabe D
J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):102-9. PubMed ID: 27186364
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
17. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes.
Zhuo M; Hawley CE; Paik JM; Bessette LG; Wexler DJ; Kim DH; Tong AY; Kim SC; Patorno E
JAMA Netw Open; 2021 Oct; 4(10):e2130762. PubMed ID: 34705014
[TBL] [Abstract][Full Text] [Related]
18. Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia.
Nyström T; Bodegard J; Nathanson D; Thuresson M; Norhammar A; Eriksson JW
Diabetes Res Clin Pract; 2017 Jan; 123():199-208. PubMed ID: 28056431
[TBL] [Abstract][Full Text] [Related]
19. Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases.
Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Yan Y; Al-Aly Z
Diabetes Care; 2020 Nov; 43(11):2859-2869. PubMed ID: 32938746
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A meta-analysis based on propensity score-matched studies.
Xu L; Zheng XQ; Liao XX
Prim Care Diabetes; 2022 Feb; 16(1):207-210. PubMed ID: 34953749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]